Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $270.89, a high estimate of $284.00, and a low estimate of $260.00. This upward ...

Mediolanum International Funds Ltd has supercharged its investment in Regeneron Pharmaceuticals, increasing its stake by a ...